1. Herman WH, Zimmet P. Type 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care 2012; 35(5): 943-4.
2. Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 2012; 19(2): 93-6.
3. Liu M, Zhou L, Xu A, et al. A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc Natl Acad Sci U S A 2008; 105(47): 18302-7.
4. Böttner M, Christoffel J, Rimoldi G, et al. Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on the pituitary-thyroid-axis. Exp Clin Endocrinol Diabetes 2006; 114(02): 82-90.
5. Giuliani C, Bucci I, Di Santo S, et al. Resveratrol inhibits sodium/iodide symporter gene expression and function in rat thyroid cells. PloS One 2014; 9(9): e107936.
6. Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008; 34(1): 8-12.
7. Izadi M, Zarifian A, Eghdami A, et al. Relationship between cardiovascular risk factors and blood adiponectin in diabetic males. Iranian South Med J 2012;15(2):101-8.
8. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360(9326): 57-8.
9. Eseberri I, Lasa A, Churruca I, et al. Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. PLoS One 2013; 8(5): e63918.
10. Habauzit V, Morand C. Evidence for a protective effect of polyphenols-containing foods on cardiovascular health: an update for clinicians. Ther Adv Chronic Dis 2012; 3(2): 87-106.
11. Juhasz B, Varga B, Gesztelyi R, et al. Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol 2010; 11(8): 810-8.
12. Giovinazzo G, Ingrosso I, Paradiso A, et al. Resveratrol biosynthesis: plant metabolic engineering for nutritional improvement of food. Plant Foods Hum Nutr 2012; 67(3): 191-9.
13. Wu JM, Wang Z-R, Hsieh T-C, et al. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine. Int J Mol Med 2001; 8(1): 3-17.
14. Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106(3): 383-9.
15. Bashmakov YK, Assaad-Khalil S, Petyaev IM. Resveratrol may be beneficial in treatment of diabetic foot syndrome. Med Hypotheses 2011; 77(3): 364-7.
16. Movahed A, Nabipour I, Lieben Louis X, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med 2013: 1-11.
17. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012; 32(7): 537-41.
18. Vang O, Ahmad N, Baile CA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PloS One 2011; 6(6): e19881.
19. Franco J, Lisboa P, da Silva Lima N, et al. Resveratrol prevents hyperleptinemia and central leptin resistance in adult rats programmed by early weaning. Horm Metab Res 2014; 46(10): 728-35.
20. Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemiamediated oxidative stress and renal inflammatory cytokines via Nrf2–Keap1 signaling. Biochim Biophys Acta 2011; 1812(7): 719-31.
21. Tomé-Carneiro J, Gonzálvez M, Larrosa M, et al .Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a tripleblind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2013; 27(1): 37-48.
22. Costa Cdos S, Rohden F, Hammes TO, et al. Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARγ1–3 mRNA expression in human visceral adipocytes. Obes Surg 2011; 21(3): 356-61.
23. Szkudelska K, Nogowski L, Szkudelski T. The inhibitory effect of resveratrol on leptin secretion from rat adipocytes. Eur J Clin Invest 2009; 39(10): 899-905.